Medicare Part D Drug Plans Face Premium Increases and Shrinking Options in 2027
The Kaiser Family Foundation found that standalone Part D prescription drug plans will see reduced availability and mixed premium impacts for 2026 enrollees, with the number of plans dropping from 11 to 9 nationally. Approximately 4 million beneficiaries who paid no monthly premiums in 2026 will face higher costs in 2027 following the end of a premium stabilization program. Meanwhile, Devoted Health secured $1.2 billion in financing to expand its Medicare Advantage operations.
The Kaiser Family Foundation's analysis reveals a contracting prescription drug plan market that has been declining for four consecutive years. While some beneficiaries enrolled in continuing plans may experience modest premium reductions, others face substantially higher costs—particularly the approximately 4 million individuals who previously paid nothing monthly. This shift directly results from the expiration of a federal premium stabilization initiative, contradicting administration statements that beneficiaries would see minimal effects from the program's conclusion.
These changes could create administrative burden for millions of seniors, potentially forcing difficult plan switches to manage costs. Reduced plan availability may limit beneficiary choice and competitive pricing, while premium increases could strain fixed incomes and affect medication adherence. The gap between "modest" and "steep" increases across different states suggests uneven impacts based on geography. However, broader implications depend on whether seniors successfully navigate plan alternatives and whether any offsetting policy interventions emerge.